{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:18:03Z","timestamp":1758845883345,"version":"3.44.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tenofovir disoproxil fumarate\/lamivudine\/dolutegravir (TLD) is widely prescribed in low and middle-income countries. Data on long-term outcomes are limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We included all persons with HIV (PWH) \u226515 years of age who initiated or switched to TLD in Port-au-Prince, Haiti. We described treatment outcomes by pre-switch viral load and assessed predictors of virologic failure using multivariable logistic regression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 10 354 PWH initiated or switched to TLD from November 2018 to March 2021, and were included in the analyses. Of these, 2217 (21.4%) were ART-na\u00efve and 8137 (78.6%) switched from an non-nucleoside reverse transcriptase inhibitor (NNTRI)-based regimen. Median follow-up time on TLD was 2.8 years (IQR: 2.3, 3.1). HIV-1 RNA &amp;lt;1000\u2005copies\/mL was achieved at the latest measurement in 92.7% of recipients of care (RoC) with pre-switch suppression, 88.5% without pre-switch viral load, 58.3% with pre-switch failure, and 81.8% of RoC ART-na\u00efve at TLD initiation. Among treatment-experienced RoC, predictors of \u22651000\u2005copies\/mL at latest test included younger age (adjusted odds ratio [aOR]: 0.44; 95% CI: 0.34, 0.57 for age \u226550 vs &amp;lt;30 years), shorter time on ART (aOR: 0.91; 95% CI: 0.89, 0.93\/year), lower education (aOR: 1.31; 95% CI: 1.13, 1.52), and higher pre-switch viral load: (aOR: 7.23; 95% CI: 6.06, 8.63 for \u226510 000 vs &amp;lt; 1000\u2005copies\/mL).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Virologic outcomes on TLD are outstanding for PWH with pre-switch suppression. However, rates of virologic suppression are suboptimal among PWH who were ART-na\u00efve at TLD initiation, and among those with a history of pre-switch failure, additional interventions are necessary, including access to long-acting treatment regimens.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf526","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T18:50:42Z","timestamp":1756579842000},"source":"Crossref","is-referenced-by-count":0,"title":["Three-Year Outcomes After Programmatic Transitioning to Dolutegravir in the Context of Severe Civil Unrest in Haiti"],"prefix":"10.1093","volume":"12","author":[{"given":"Bernard","family":"Liautaud","sequence":"first","affiliation":[{"name":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO) , Port-au-Prince ,","place":["Haiti"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Sanchez","family":"Chico","sequence":"additional","affiliation":[{"name":"Analysis Group , Boston, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youry","family":"Macius","sequence":"additional","affiliation":[{"name":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO) , Port-au-Prince ,","place":["Haiti"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sosina","family":"Abuhay","sequence":"additional","affiliation":[{"name":"Analysis Group , Boston, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Joseph","sequence":"additional","affiliation":[{"name":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO) , Port-au-Prince ,","place":["Haiti"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harrison T","family":"Reeder","sequence":"additional","affiliation":[{"name":"Biostatistics, Massachusetts General Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3641-7898","authenticated-orcid":false,"given":"Theo","family":"Bolas","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adias","family":"Marcelin","sequence":"additional","affiliation":[{"name":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO) , Port-au-Prince ,","place":["Haiti"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colette Guiteau","family":"Mo\u00efse","sequence":"additional","affiliation":[{"name":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO) , Port-au-Prince ,","place":["Haiti"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Apollon","sequence":"additional","affiliation":[{"name":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO) , Port-au-Prince ,","place":["Haiti"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6479-0820","authenticated-orcid":false,"given":"Pierre","family":"Cremieux","sequence":"additional","affiliation":[{"name":"Analysis Group , Boston, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean W","family":"Pape","sequence":"additional","affiliation":[{"name":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO) , Port-au-Prince ,","place":["Haiti"]},{"name":"Department of Medicine, Weill Cornell Medicine , New York, New York ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7464-275X","authenticated-orcid":false,"given":"Serena P","family":"Koenig","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Medicine, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"key":"2025092508524651700_ofaf526-B1"},{"key":"2025092508524651700_ofaf526-B2"},{"key":"2025092508524651700_ofaf526-B3","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"key":"2025092508524651700_ofaf526-B4","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1097\/QAD.0000000000002254","article-title":"Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of dolutegravir","volume":"33","author":"Meireles","year":"2019","journal-title":"AIDS"},{"key":"2025092508524651700_ofaf526-B5","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1016\/S2352-3018(22)00136-9","article-title":"Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study","volume":"9","author":"Schramm","year":"2022","journal-title":"Lancet HIV"},{"key":"2025092508524651700_ofaf526-B6","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/cid\/ciab1006","article-title":"Viral load status before switching to dolutegravir-containing antiretroviral therapy and associations with human immunodeficiency virus treatment outcomes in Sub-Saharan Africa","volume":"75","author":"Romo","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025092508524651700_ofaf526-B7","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1016\/S2352-3018(23)00047-4","article-title":"Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study","volume":"10","author":"Dorward","year":"2023","journal-title":"Lancet HIV"},{"key":"2025092508524651700_ofaf526-B8","doi-asserted-by":"crossref","first-page":"e0238052","DOI":"10.1371\/journal.pone.0238052","article-title":"Dolutegravir: virologic response and tolerability of initial antiretroviral regimens for adults living with HIV","volume":"15","author":"Correa","year":"2020","journal-title":"PLoS One"},{"key":"2025092508524651700_ofaf526-B9","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/S2214-109X(23)00516-8","article-title":"Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study","volume":"12","author":"Asare","year":"2024","journal-title":"Lancet Glob Health"},{"key":"2025092508524651700_ofaf526-B10","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/cid\/ciad390","article-title":"Two-year outcomes of treatment-experienced adults after programmatic transitioning to dolutegravir: longitudinal data from the VICONEL human immunodeficiency virus cohort in Lesotho","volume":"77","author":"Tschumi","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025092508524651700_ofaf526-B11","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3390\/v16030399","article-title":"Prevalence of emergent dolutegravir resistance mutations in people living with HIV: a rapid scoping review","volume":"16","author":"Chu","year":"2024","journal-title":"Viruses"},{"author":"Ismail","key":"2025092508524651700_ofaf526-B12"},{"author":"Kalata","key":"2025092508524651700_ofaf526-B13","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003744"},{"author":"Namayanja","key":"2025092508524651700_ofaf526-B14"},{"author":"Parikh","key":"2025092508524651700_ofaf526-B15"},{"key":"2025092508524651700_ofaf526-B16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/QAI.0000000000003065","article-title":"Brief report: virologic impact of the dolutegravir transition: prospective results from the multinational African cohort study","volume":"91","author":"Allahna","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"volume-title":"HIV Drug resistance. Brief report 2024","year":"2024","key":"2025092508524651700_ofaf526-B17"},{"author":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services","key":"2025092508524651700_ofaf526-B18"},{"key":"2025092508524651700_ofaf526-B19"},{"key":"2025092508524651700_ofaf526-B20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"2025092508524651700_ofaf526-B21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAD.0000000000003070","article-title":"Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy\u2014naive adults with HIV-1 infection","volume":"36","author":"Cahn","year":"2022","journal-title":"AIDS"},{"key":"2025092508524651700_ofaf526-B22","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025092508524651700_ofaf526-B23","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/ciac036","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the phase 3, noninferiority TANGO randomized trial","volume":"75","author":"Osiyemi","year":"2022","journal-title":"Clin Infect Dis"},{"author":"Veras","key":"2025092508524651700_ofaf526-B24"},{"key":"2025092508524651700_ofaf526-B25"},{"key":"2025092508524651700_ofaf526-B26"},{"key":"2025092508524651700_ofaf526-B27"},{"key":"2025092508524651700_ofaf526-B28"},{"key":"2025092508524651700_ofaf526-B29","article-title":"Virologic and resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in PEPFAR-supported countries: an observational cohort study","author":"Marc","year":"2025","journal-title":"Lancet HIV"},{"key":"2025092508524651700_ofaf526-B30","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1016\/S2352-3018(24)00208-X","article-title":"GHESKIO's model of patient care during civil unrest in Haiti","volume":"11","author":"Deschamps","year":"2024","journal-title":"Lancet HIV"},{"key":"2025092508524651700_ofaf526-B31","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/2325957417742670","article-title":"Retention in care among patients with early HIV disease in Haiti","volume":"16","author":"Hennessey","year":"2017","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2025092508524651700_ofaf526-B32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/QAI.0000000000001725","article-title":"A successful model of expedited antiretroviral therapy for clinically stable patients living with HIV in Haiti","volume":"79","author":"Guiteau Moise","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 2","key":"2025092508524651700_ofaf526-B33","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1097\/QAD.0000000000003082","article-title":"Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era","volume":"35","author":"McCluskey","year":"2021","journal-title":"AIDS"},{"key":"2025092508524651700_ofaf526-B34","doi-asserted-by":"crossref","first-page":"e1008","DOI":"10.1093\/cid\/ciab086","article-title":"Participants on dolutegravir resuppress human immunodeficiency virus RNA after virologic failure: updated data from the ADVANCE trial","volume":"73","author":"Pepperrell","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025092508524651700_ofaf526-B35","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/QAD.0000000000002936","article-title":"Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen","volume":"35","author":"Keene","year":"2021","journal-title":"AIDS"},{"key":"2025092508524651700_ofaf526-B36","doi-asserted-by":"crossref","first-page":"e733","DOI":"10.1016\/S2352-3018(23)00228-X","article-title":"HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis","volume":"10","author":"Loosli","year":"2023","journal-title":"Lancet HIV"},{"key":"2025092508524651700_ofaf526-B37","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1097\/QAD.0000000000003653","article-title":"First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir\/lamivudine\/dolutegravir use in mothers","volume":"37","author":"Francois","year":"2023","journal-title":"AIDS"},{"issue":"1):","key":"2025092508524651700_ofaf526-B38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/jama.2025.5180","article-title":"Long-acting HIV treatment in low- and middle-income countries: addressing the public health need","volume":"334","author":"Ehrenkranz","year":"2025","journal-title":"JAMA"},{"author":"Sivile","key":"2025092508524651700_ofaf526-B39"},{"key":"2025092508524651700_ofaf526-B40","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/hiv.13189","article-title":"Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: a prospective cohort study in Lesotho (DO-REAL study)","volume":"23","author":"Brown","year":"2022","journal-title":"HIV Med"},{"key":"2025092508524651700_ofaf526-B41","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/QAD.0000000000002223","article-title":"Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials","volume":"33","author":"Gupta","year":"2019","journal-title":"AIDS"},{"key":"2025092508524651700_ofaf526-B42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12981-019-0227-1","article-title":"Tenofovir-associated kidney disease in Africans: a systematic review","volume":"16","author":"Mtisi","year":"2019","journal-title":"AIDS Res Ther"},{"key":"2025092508524651700_ofaf526-B43","doi-asserted-by":"crossref","first-page":"ofad666","DOI":"10.1093\/ofid\/ofad666","article-title":"Combined \u201ctest and treat\u201d campaigns for human immunodeficiency virus, hepatitis B, and hepatitis C: a systematic review to provide evidence to support world health organization treatment guidelines","volume":"11","author":"Beard","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2025092508524651700_ofaf526-B44","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2352-3018(24)00061-4","article-title":"Two-drug regimens for the treatment of HIV in Africa","volume":"11","author":"Mambule","year":"2024","journal-title":"Lancet HIV"},{"key":"2025092508524651700_ofaf526-B45","doi-asserted-by":"crossref","first-page":"ofad526","DOI":"10.1093\/ofid\/ofad526","article-title":"Virologic response to dolutegravir plus lamivudine in people with suppressed human immunodeficiency virus type 1 and historical M184V\/I: a systematic literature review and meta-analysis","volume":"10","author":"Kabra","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025092508524651700_ofaf526-B46"},{"key":"2025092508524651700_ofaf526-B47","doi-asserted-by":"crossref","first-page":"e0254331","DOI":"10.1371\/journal.pone.0254331","article-title":"Evaluation of a community-based HIV test and start program in a conflict affected rural area of Yambio County, South Sudan","volume":"16","author":"Ferreyra","year":"2021","journal-title":"PLoS One"},{"key":"2025092508524651700_ofaf526-B48","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13031-018-0161-1","article-title":"Provision and continuation of antiretroviral therapy during acute conflict: the experience of MSF in Central African Republic and Yemen","volume":"12","author":"Ferreyra","year":"2018","journal-title":"Confl Health"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf526\/64167872\/ofaf526.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/9\/ofaf526\/64167872\/ofaf526.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/9\/ofaf526\/64167872\/ofaf526.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:52:58Z","timestamp":1758804778000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf526\/8244740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,8,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf526","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,29]]},"article-number":"ofaf526"}}